Anti Thrombin III

Overview

The document describes Anti Thrombin III (AT III) as a naturally occurring anticoagulant protein belonging to the serine protease inhibitor family. It is synthesized primarily in the liver, with additional production from endothelial cells. AT III neutralizes key coagulation enzymes, including thrombin, Factor Xa, IXa, XIa, and XIIa, helping maintain a healthy balance between clot formation and dissolution.

Anti Thrombin III activity is significantly enhanced in the presence of heparin, increasing its anticoagulant action by nearly 1000 times. This makes AT III essential not only for natural clot control but also for the therapeutic effectiveness of heparin.

The protein exists in plasma as α-antithrombin and β-antithrombin, and a deficiency in either the congenital or acquired form increases the risk of venous thromboembolism (VTE). The document highlights AT III as one of the most important coagulation inhibitors, with additional anti-inflammatory properties. Because of its critical role in coagulation pathways, Anti Thrombin III testing is widely used to diagnose clotting disorders, monitor anticoagulant therapy, and evaluate unexplained clotting tendencies.

Symptoms

Symptoms associated with Anti-Thrombin III deficiency arise from an increased tendency to form abnormal clots. The document’s symptom chart lists several key presentations:

1. Leg swelling
2. Leg pain
3. Shortness of breath
4. Chest pain
5. Palpitations
6. Headache
7. Abdominal pain
8. Visual disturbances
9. Recurrent pregnancy loss

These symptoms reflect underlying thromboembolic events such as deep vein thrombosis (DVT), pulmonary embolism, microvascular clotting, or placental thrombosis. AT III deficiency rarely causes symptoms on its own; symptoms appear when clots form and impair circulation or organ perfusion.

Causes

The document identifies both congenital and acquired causes of Anti Thrombin III deficiency:

1. Congenital AT III Deficiency

An inherited condition that significantly increases the risk of VTE. Individuals with this form are often diagnosed in adolescence or adulthood after experiencing unexplained thrombotic episodes.

2. Acquired AT III Deficiency

Occurs in various medical conditions that alter synthesis, increase consumption, or reduce circulating AT III levels. Document-listed causes include:

1. Liver disease (reduced synthesis)
2. Disseminated Intravascular Coagulation (DIC)
3. Sepsis
4. Nephrotic syndrome (loss of AT III through urine)
5. Surgery, especially liver transplant or major bypass procedures
6. Hyperfibrinolysis, reducing AT III concentration

3. Heparin Resistance

The document notes that low AT III levels can cause resistance to heparin, making anticoagulation less effective during cardiopulmonary bypass, ECMO, or other high-risk procedures.

4. Cancer and Critical Illness

Conditions such as Veno-Occlusive Disease (VOD), organ transplantation, and certain chemotherapy regimens increase AT III consumption and lower functional levels.

Risk Factors

Risk factors for AT III deficiency or reduced activity include:

1. Family history of hereditary thrombophilia
2. Past venous thromboembolism, including DVT or pulmonary embolism
3. Recurrent miscarriages
4. Use of anticoagulant therapy that appears ineffective
5. Critical illness, such as sepsis or ICU admissions
6. Liver disease or nephrotic syndrome
7. Major surgeries, including liver transplant or bypass procedures
8. Active clotting disorders, including DIC
9. Cancer treatment, especially therapies linked with VOD or coagulation changes

These factors increase the probability of altered AT III activity and highlight the need for targeted testing.

Prevention

While hereditary Anti Thrombin III deficiency cannot be prevented, the document outlines several preventive strategies that help reduce complications, ensure proper testing, and guide treatment:

1. Pre-test Preparation

Before collection, patients should:

1. Discontinue medications affecting Anti Thrombin III levels, as advised by the treating clinician
2. Avoid strenuous exercise
3. Stay well hydrated

2. Correct Sample Handling

Accurate AT III measurement requires:

1. Collecting blood in a sodium citrate (light blue-capped) tube
2. Using the exact volume specified
3. Proper mixing
4. Centrifuging to obtain platelet-poor plasma and sending it promptly to the lab

3. Early Identification of At-Risk Individuals

Testing is recommended for individuals with recurrent VTE, heparin resistance, recurrent pregnancy loss, or a strong family history of Anti Thrombin III deficiency.

4. Monitoring During Anticoagulant Therapy

AT III levels should be monitored when anticoagulant therapy is ineffective or when managing clotting disorders during surgery, ECMO, or critical illness.

5. Management of Underlying Conditions

Addressing sepsis, liver disease, nephrotic syndrome, or DIC helps restore AT III balance and reduce clotting complications.

6. Clinical Correlation

The document emphasizes thatAnti Thrombin III test results must always be interpreted alongside clinical findings to avoid misdiagnosis.